Terms: = Ovarian cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Treatment
319 results:
1. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
2. Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer.
Kim K; Kim H; Shin I; Noh SJ; Kim JY; Suh KJ; Kim YN; Lee JY; Cho DY; Kim SH; Kim JH; Lee SH; Choi JK
Sci Rep; 2023 Dec; 13(1):22482. PubMed ID: 38110532
[TBL] [Abstract] [Full Text] [Related]
3. The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death.
Koyanagi T; Saga Y; Takahashi Y; Tamura K; Yoshiba T; Takahashi S; Taneichi A; Takei Y; Mizukami H; Fujiwara H
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1934. PubMed ID: 38013666
[TBL] [Abstract] [Full Text] [Related]
4. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review.
Taliento C; Restaino S; Scutiero G; Arcieri M; Bernardi G; Martinello R; Driul L; Perrone AM; Fagotti A; Scambia G; Greco P; Vizzielli G
Eur J Surg Oncol; 2023 Dec; 49(12):107250. PubMed ID: 37951158
[TBL] [Abstract] [Full Text] [Related]
5. The effect of growth hormone on ovarian function recovery in a mouse model of ovarian insufficiency.
Kim SM; Yoo JY; Hong YH; Lee J; Kim JH; Lee JR
Front Endocrinol (Lausanne); 2023; 14():1184977. PubMed ID: 37854196
[TBL] [Abstract] [Full Text] [Related]
6. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate cancer.
Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang KC; Poon V; Sutaria DS; Gurney H
Clin Cancer Res; 2023 Sep; 29(17):3292-3300. PubMed ID: 37339186
[TBL] [Abstract] [Full Text] [Related]
7. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Eur J Cancer; 2023 Aug; 189():112908. PubMed ID: 37263896
[TBL] [Abstract] [Full Text] [Related]
8. Microsatellite instability in non-endometrioid ovarian epithelial tumors: a study of 400 cases comparing immunohistochemistry, PCR, and NGS based testing with mutation status of MMR genes.
Hájková N; Bártů MK; Cibula D; Drozenová J; Fabian P; Fadare O; Frühauf F; Hausnerová J; Hojný J; Krkavcová E; Laco J; Lax SF; Matěj R; Méhes G; Michálková R; Němejcová K; Singh N; Stolnicu S; Švajdler M; Zima T; McCluggage WG; Stružinská I; Dundr P
Transl Res; 2023 Oct; 260():61-68. PubMed ID: 37244485
[TBL] [Abstract] [Full Text] [Related]
9. Supervised resistance exercise for women with ovarian cancer who have completed first-line treatment: a pragmatic study.
Schofield C; Newton RU; Taaffe DR; Galvão DA; Cohen PA; Meniawy TM; Peddle-McIntyre CJ
Support Care Cancer; 2023 Apr; 31(5):304. PubMed ID: 37101013
[TBL] [Abstract] [Full Text] [Related]
10. [Olaparib Could Be Re-Administered after Chemotherapy].
Terasawa R; Takashima Y; Hirata A; Kimura K; Morita S; Hayashi M
Gan To Kagaku Ryoho; 2023 Apr; 50(4):473-475. PubMed ID: 37066460
[TBL] [Abstract] [Full Text] [Related]
11. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Pignata S; Oza A; Hall G; Pardo B; Madry R; Cibula D; Klat J; Montes A; Glasspool R; Colombo N; Pete I; Herrero Ibáñez A; Marín MR; Ilieva R; Timcheva C; Di Maio M; Blakeley C; Taylor R; Barnicle A; Clamp A
Gynecol Oncol; 2023 May; 172():121-129. PubMed ID: 37030280
[TBL] [Abstract] [Full Text] [Related]
12. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
Chekerov R; Arndt T; Pietzner K; Canzler U; Wimberger P; Strauß HG; Mahner S; Woelber L; de Gregorio N; Stocker G; von Abel E; Neunhoeffer T; Belau AK; Mustea A; Yalinkaya I; Braicu EI; Richter R; Sehouli J;
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7637-7649. PubMed ID: 37000264
[TBL] [Abstract] [Full Text] [Related]
13. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Senkus E; Delaloge S; Domchek SM; Conte P; Im SA; Xu B; Armstrong A; Masuda N; Fielding A; Robson M; Tung N
Int J Cancer; 2023 Aug; 153(4):803-814. PubMed ID: 36971103
[TBL] [Abstract] [Full Text] [Related]
14. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
Foster KI; Shaw KRM; Jin J; Westin SN; Yap TA; Glassman DM; Jazaeri AA; Rauh-Hain JA; Lee S; Fellman BM; Ju Z; Liu Y; Fleming ND; Sood AK
Cancer; 2023 Jun; 129(11):1672-1680. PubMed ID: 36930815
[TBL] [Abstract] [Full Text] [Related]
15. Curcumol, a major terpenoid from Curcumae Rhizoma, attenuates human uterine leiomyoma cell development via the p38MAPK/NF-κB pathway.
Yu YH; Zhang HJ; Yang F; Xu L; Liu H
J Ethnopharmacol; 2023 Jun; 310():116311. PubMed ID: 36894110
[TBL] [Abstract] [Full Text] [Related]
16. The Efficacy and Safety of Pazopanib Plus Chemotherapy in Treating Recurrent or Persistent ovarian cancer: A Systematic Review and Meta-Analysis.
Zhang Y; Fang H; Wang X; Wang H; Pan G; Chen J
Am J Clin Oncol; 2023 Jun; 46(6):254-262. PubMed ID: 36877187
[TBL] [Abstract] [Full Text] [Related]
17. VSELs and OSCs together sustain oogenesis in adult ovaries and their dysfunction results in age-related senescence, PCOS, POI and cancer.
Bhartiya D; Sharma D
J Ovarian Res; 2023 Feb; 16(1):29. PubMed ID: 36726163
[TBL] [Abstract] [Full Text] [Related]
18. The use of Ctrough for the therapeutic drug monitoring of olaparib in patients with ovarian cancer.
Stanisławiak-Rudowicz J; Szałek E; Grzebalska M; Urjasz H; Michalak M; Mądry R; Grześkowiak E
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(24):9426-9436. PubMed ID: 36591851
[TBL] [Abstract] [Full Text] [Related]
19. Deciphering sex-specific miRNAs as heat-recorders in zebrafish.
van Gelderen TA; Montfort J; Álvarez-Dios JA; Thermes V; Piferrer F; Bobe J; Ribas L
Sci Rep; 2022 Nov; 12(1):18722. PubMed ID: 36333360
[TBL] [Abstract] [Full Text] [Related]
20. A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol.
Sharma A; Johnson KB; Bie B; Rhoades EE; Sen A; Kida Y; Hockings J; Gatta A; Davenport J; Arcangelini C; Ritzu J; DeVecchio J; Hughen R; Wei M; Thomas Budd G; Lynn Henry N; Eng C; Foss J; Rotroff DM
Technol Cancer Res Treat; 2022; 21():15330338221127169. PubMed ID: 36172750
[No Abstract] [Full Text] [Related]
[Next]
